Advertisement
RCUS vs VIR
Which Stock Would AI Choose? Arcus Biosciences (RCUS) vs. Vir Biotechnology (VIR) Stock Comparison
Key Takeaways
- RCUS is an oncology-focused, clinical-stage biotech whose shares have experienced sharp momentum swings tied to late-stage trial news.
- VIR combines infectious disease and oncology programs, supported by partnerships that extend its cash runway well beyond the near term.
- Both companies remain unprofitable and depend heavily on binary clinical catalysts, making them higher-volatility names than established biopharma peers.
- RCUS currently carries stronger near-term relative performance and a more concentrated late-stage pipeline, while VIR offers broader diversification across therapeutic areas.
- The divergence in analyst price targets and recent momentum suggests different risk-reward profiles for traders and long-term investors.
Introduction
This stock comparison examines two clinical-stage biotechnology companies that have drawn investor attention for sharply different reasons. RCUS (Arcus Biosciences) is a cancer immunotherapy developer whose shares rallied strongly before a late-stage setback triggered a pullback. VIR (Vir Biotechnology) spans infectious diseases and oncology, leaning on partnerships to fund a multi-year pipeline. Both are speculative, catalyst-driven equities where relative performance is shaped more by trial data and collaboration news than by near-term earnings. This comparison is most relevant to traders and investors who are comfortable with elevated volatility and who evaluate biotech positions primarily on pipeline quality, cash position, and clinical milestones rather than current profitability.
RCUS Overview and Recent Performance
Arcus Biosciences (RCUS) develops small-molecule immuno-oncology therapies. Its lead programs include casdatifan, a HIF-2α (hypoxia-inducible factor-2 alpha) inhibitor for kidney cancer, and quemliclustat, a CD73 inhibitor being studied in pancreatic cancer. A strategic partnership with Gilead Sciences, which holds roughly a 25% ownership stake, underpins much of the pipeline.
Recent market activity has been volatile. After a multi-month rally of several hundred percent from a spring low, the shares reversed lower when a Phase 3 trial of domvanalimab, an anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) drug, failed to show a survival benefit in gastric cancer, prompting discontinuation of that program. Investors have since refocused on casdatifan, which the company fully owns outside Japan and select Asian territories. Quarterly results continue to show net losses, and Wall Street price targets span a wide range, reflecting the binary nature of the pipeline.
VIR Overview and Recent Performance
Vir Biotechnology (VIR) is an immunology company developing medicines for serious infectious diseases and cancer. Its lead infectious disease franchise targets chronic hepatitis delta, an underserved liver condition, through the combination of tobevibart and elebsiran. In oncology, the company is advancing dual-masked T-cell engagers (TCEs), including an early-stage program in prostate cancer.
Recent weeks have been defined by partnership activity rather than standalone data. A global oncology collaboration with Astellas and a licensing agreement with Norgine for hepatitis delta commercialization have helped extend the company's cash runway, which management has indicated should fund operations into 2028. Financial results still show meaningful net losses, and the stock has lagged the broader market for much of the year. Analysts have raised price targets on the Astellas collaboration and early oncology data, though the shares remain well below consensus target levels, reflecting persistent execution uncertainty.
Trending AI Robots
For traders seeking a systematic edge in names like RCUS and VIR, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading strategies. Tickeron hosts hundreds of AI trading bots that collectively monitor thousands of tickers, but only the strongest and most suitable for current market conditions earn a place in this rotating selection. Each bot operates with its own trading style, strategy, timeframe, performance history, statistics, and universe of stocks, so no two approaches are identical. The featured robots are evaluated and refreshed based on recent results and market fit, giving visitors a filtered starting point instead of an overwhelming list. Explore the Trending AI Robots section to see which automated strategies are currently standing out.
Head-to-Head Comparison
The clearest contrast between these two names is focus. RCUS concentrates almost entirely on oncology, with a smaller number of late-stage assets and meaningful reliance on Gilead. This creates concentrated upside but also concentrated risk, as the domvanalimab failure demonstrated. VIR spreads its bets across hepatitis delta and a TCE oncology platform, and its Astellas and Norgine deals reduce development-cost burden and funding risk.
On relative performance, RCUS has shown stronger recent momentum and a bullish options skew, while VIR has underperformed for much of the year despite a longer cash runway into 2028. Both companies generate modest revenue relative to their research and development (R&D) spending and report recurring net losses. Sector exposure also differs: RCUS sits squarely in competitive immuno-oncology, whereas VIR benefits from a relatively underserved hepatitis delta market alongside oncology optionality. In short, RCUS offers a more concentrated, momentum-driven profile, while VIR offers diversification and a longer funding horizon at the cost of slower visible catalysts.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative positioning, and near-term catalysts, Tickeron's AI framework would likely lean toward RCUS in the current environment. The stock's stronger recent relative performance, bullish sentiment signals, and higher average analyst price targets suggest more favorable momentum, even after accounting for the domvanalimab setback. VIR carries a more stable funding profile and a diversified pipeline, but its slower catalyst cadence and weaker year-to-date trend reduce its near-term appeal from a momentum standpoint. This is a probabilistic assessment rather than a definitive forecast, and the ranking could shift quickly as either company reports new clinical or partnership data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RCUS is a Hold and VIR is a Hold.
RCUS in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 21, 2026
RCUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 32 cases where RCUS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for RCUS's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 61 cases where RCUS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +7.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCUS advanced for three days, in 219 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RCUS as a result. In 76 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for RCUS turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 38 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for RCUS entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. RCUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.242) is normal, around the industry mean (2.988). P/E Ratio (-4.848) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (25.063) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
VIR sees MACD Histogram crosses below signal line
VIR saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 13, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In 36 of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VIR as a result. In 75 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
VIR moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 202 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
VIR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 115 of 159 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.820) is normal, around the industry mean (2.988). P/E Ratio (-5.972) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RCUS | VIR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 26 | 65 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 64 Fair valued | 22 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 96 | |
PRICE GROWTH RATING 1..100 | 58 | 40 | |
P/E GROWTH RATING 1..100 | 24 | 58 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VIR's Valuation (22) in the null industry is somewhat better than the same rating for RCUS (64) in the Pharmaceuticals Major industry. This means that VIR’s stock grew somewhat faster than RCUS’s over the last 12 months.
VIR's Profit vs Risk Rating (100) in the null industry is in the same range as RCUS (100) in the Pharmaceuticals Major industry. This means that VIR’s stock grew similarly to RCUS’s over the last 12 months.
VIR's SMR Rating (96) in the null industry is in the same range as RCUS (98) in the Pharmaceuticals Major industry. This means that VIR’s stock grew similarly to RCUS’s over the last 12 months.
VIR's Price Growth Rating (40) in the null industry is in the same range as RCUS (58) in the Pharmaceuticals Major industry. This means that VIR’s stock grew similarly to RCUS’s over the last 12 months.
RCUS's P/E Growth Rating (24) in the Pharmaceuticals Major industry is somewhat better than the same rating for VIR (58) in the null industry. This means that RCUS’s stock grew somewhat faster than VIR’s over the last 12 months.
| RCUS | VIR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 85% | N/A |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 72% |
| Momentum ODDS (%) | 2 days ago 83% | 2 days ago 82% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 86% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 77% | 2 days ago 77% |
| Advances ODDS (%) | 3 days ago 78% | 3 days ago 76% |
| Declines ODDS (%) | 10 days ago 78% | 9 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 88% | 2 days ago 74% |
| Aroon ODDS (%) | 2 days ago 79% | 2 days ago 72% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RCUS’s FA Score shows that 1 FA rating(s) are green while VIR’s FA Score has 1 green FA rating(s).
- RCUS’s FA Score: 1 green, 4 red.
- VIR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RCUS’s TA Score shows that 4 TA indicator(s) are bullish while VIR’s TA Score has 4 bullish TA indicator(s).
- RCUS’s TA Score: 4 bullish, 4 bearish.
- VIR’s TA Score: 4 bullish, 4 bearish.
Price Growth
RCUS (@Biotechnology) experienced а -15.22% price change this week, while VIR (@Biotechnology) price change was +1.54% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.20%, and the average quarterly price growth was -15.34%.
Reported Earning Dates
RCUS is expected to report earnings on Oct 27, 2026.
VIR is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
RCUS and
Correlation & Price change
A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with VIR. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To RCUS | 1D Price Change % | ||
|---|---|---|---|---|
| RCUS | 100% | -19.58% | ||
| VIR - RCUS | 49% Loosely correlated | -1.58% | ||
| XNCR - RCUS | 49% Loosely correlated | +0.88% | ||
| KURA - RCUS | 46% Loosely correlated | -1.00% | ||
| NRIX - RCUS | 44% Loosely correlated | -0.31% | ||
| BCAX - RCUS | 44% Loosely correlated | -2.40% | ||
More | ||||
VIR and
Correlation & Price change
A.I.dvisor indicates that over the last year, VIR has been loosely correlated with BEAM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To VIR | 1D Price Change % | ||
|---|---|---|---|---|
| VIR | 100% | -1.58% | ||
| BEAM - VIR | 55% Loosely correlated | -0.36% | ||
| DNLI - VIR | 53% Loosely correlated | -1.32% | ||
| EDIT - VIR | 52% Loosely correlated | -2.71% | ||
| PRME - VIR | 51% Loosely correlated | -2.81% | ||
| RCUS - VIR | 51% Loosely correlated | -19.58% | ||
More | ||||